Marjorie Roesser

Cooley advised Mirum Pharmaceuticals on its $275 million aggregate principal amount of 4.00% convertible senior notes due 2029. Mirum is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Jason Kent and Jason Savich led the Cooley team.

Cooley advised the underwriters in Pliant Therapeutics’ $230.0 million follow-on offering of 12,432,432 shares of common stock at a public offering price of $18.50 per share. Pliant is a clinical-stage biotechnology company discovering and developing novel therapies for the treatment of fibrosis. Partners Denny Won, Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team.

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.

Cooley advised the underwriters on fashion brand Lulu’s $92 million initial public offering of 5,750,000 shares of common stock, which now trade on the Nasdaq Global Market under the symbol LVLU. Lawyers David Peinsipp, Kristin VanderPas and Denny Won led the Cooley team advising the underwriters.

Cooley advised the underwriters on PROCEPT BioRobotics’ $188.5 million initial public offering of 7,539,400 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. BofA Securities, Inc. and Goldman Sachs & Co. LLC acted as joint lead book-running managers for the offering. PROCEPT BioRobotics, whose securities now trade on the Nasdaq Global Market under the symbol “PRCT,” is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Partners Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team.